National Organization for Rare Disorders Honors Biopharma Innovators, Scientists, and Advocates with 2026 Rare Impact Awards

The National Organization for Rare Disorders (NORD®) has announced its distinguished slate of honorees for the annual NORD Rare Impact Awards®, recognizing a vanguard of biopharma industry leaders, medical scientists, and patient advocates. These individuals and organizations are being celebrated for their extraordinary contributions to improving the lives of the more than 30 million Americans who are currently living with a rare disease.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

The 2026 honorees encompass a diverse cross-section of the healthcare ecosystem. They include innovative pharmaceutical companies whose cutting-edge treatments have radically improved rare disease patient outcomes, grassroots community leaders raising vital public awareness, trailblazing medical scientists pushing the boundaries of rare disease research, and dedicated advocates spearheading transformative legislative and policy changes across their respective states.

Industry Innovators in Rare Disease

Among this year’s most anticipated recognitions are five pioneering biopharmaceutical companies and one dedicated nonprofit organization—working hand-in-hand with impacted rare disease patient communities—that have celebrated recent landmark U.S. Food and Drug Administration (FDA) approvals for first-of-their-kind therapies.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

With approximately 95% of the more than 10,000 known rare diseases still lacking a single approved treatment, the acceleration of scientific progress remains an urgent imperative for global healthcare.

"With approximately 95% of more than 10,000 known rare diseases still lacking an approved treatment, advancing scientific progress is critical," said Pamela K. Gavin, NORD Chief Executive Officer. "NORD is proud to honor these companies and nonprofit organizations for pioneering new therapies and advancing research that can change what is possible for individuals and families affected by these rare diseases. Their progress in addressing the unique challenges of these conditions is also contributing knowledge, approaches, and breakthroughs that help move science and the entire rare disease field forward."

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

The 2026 Industry Innovator honorees represent transformative leaps in therapeutic development. Mighty Therapeutics is being honored for FORZINITY™, the first-ever therapy approved for Barth syndrome. Barth syndrome is an extremely rare, progressive, and life-limiting genetic condition that directly affects cellular mitochondria, leading to impaired muscle strength and a diminished quality of life. Barth syndrome advocates, notably NORD Member the Barth Syndrome Foundation, championed the development of this therapy for over a decade, helping secure its crucial accelerated approval. The arrival of FORZINITY brings profound hope not only to families managing Barth syndrome but also to the broader community facing rare mitochondrial diseases, who have lauded the approval as a monumental step forward for research and regulatory pathways.

UCB has earned recognition for KYGEVVI®, the first and only FDA-approved treatment specifically indicated for adults and children suffering from thymidine kinase 2 deficiency (TK2d) whose symptom onset occurred at or before 12 years of age. Clinical data has demonstrated that KYGEVVI reduces the risk of death by over 90%, with 75% of patients regaining at least one previously lost motor skill, and many successfully reducing or eliminating their reliance on ventilatory support. This milestone was jubilantly celebrated by NORD Member organizations including the United Mitochondrial Disease Foundation, MitoAction, and the Muscular Dystrophy Association, all of which spent years investing heavily in foundational mitochondrial disease research.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Fondazione Telethon is being honored for Waskyra™, a breakthrough gene therapy designed to treat Wiskott-Aldrich syndrome (WAS). Developed through decades of meticulous research at the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy, WAS is a genetically inherited form of primary immunodeficiency (PI) and stands as the first PI to receive an FDA-approved gene therapy. Furthermore, Waskyra marks a historic milestone as the first instance of a nonprofit organization independently developing and bringing a gene therapy to the commercial market. The achievement was celebrated by NORD Member the Immune Deficiency Foundation.

Omeros has been recognized for YARTEMLEA®, the first and only FDA-approved treatment for adults and children aged two years and older diagnosed with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). This severe and frequently fatal complication of stem cell transplantation arises from endothelial cell injury, triggering microscopic blood clots in small blood vessels that compromise vital organ function. Bone marrow transplant advocacy groups and leading medical institutions specializing in cellular transplantation have lauded the approval of YARTEMLEA as a targeted, potentially life-saving intervention.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Jazz Pharmaceuticals has been honored for MODEYSO™, the first and only FDA-approved treatment for recurrent H3K27M-mutant diffuse midline glioma (DMG), one of the most aggressive and devastating brain tumors affecting children and young adults. Approximately 2,000 families across the United States receive this heartbreaking rare cancer diagnosis annually. The patient community spent more than a decade funding and participating in the foundational research that ultimately made this clinical breakthrough possible. By securing accelerated approval for a new therapeutic option in H3K27M-mutant DMG, Jazz Pharmaceuticals has offered patients and their families the unprecedented possibility of a new future.

Verastem Oncology is being recognized for the AVMAPKI® FAKZYNJA® CO-PACK, the first treatment specifically approved for adult patients diagnosed with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have previously undergone systemic therapy. This rare form of cancer has historically presented an exceptionally high unmet medical need, with fewer than 14% of patients exhibiting a response to traditional chemotherapy and hormone therapy regimens. With clinical response rates reaching 44%, the deployment of the AVMAPKI FAKZYNJA CO-PACK alongside routine molecular testing for KRAS mutations is widely expected to establish a new standard of care for LGSOC in clinical practice.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Individuals and Organizations Honored

Beyond industrial innovation, NORD is recognizing the exceptional dedication of individuals and grassroots organizations working tirelessly to improve daily life for the one in ten Americans navigating a rare disorder.

The Foundation for Prader-Willi Research (FPWR) has been named the recipient of the prestigious Abbey S. Meyers Leadership Award. As a dedicated NORD Member organization, FPWR leads patient-centered research initiatives focused on Prader-Willi syndrome (PWS), utilizing its Global PWS Registry, which was constructed upon NORD’s robust IAMRARE® patient registry platform. Insights harvested from this registry directly contributed to the landmark FDA approval of VYKAT™ XR, the inaugural approved treatment addressing excessive hunger—one of the most debilitating hallmark challenges of PWS. This achievement represented the first known instance of data originating from the IAMRARE platform directly driving an FDA drug approval.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Stephanie E. Haridopolos, MD, DABFM, has been honored with the Policy Changemaker Award. A board-certified family medicine physician and prominent public health official, Dr. Haridopolos has forged a distinguished career bridging hands-on clinical practice with high-level government service. Serving initially as Chief of Staff of the Office of the Surgeon General and subsequently as its Director of National Health Communications, Dr. Haridopolos has emerged as a crucial national voice for rare disease patients. Most notably, she played a vital role in facilitating the U.S. Department of Health and Human Services’ addition of Duchenne muscular dystrophy and metachromatic leukodystrophy to the Recommended Newborn Screening Panel (RUSP). Since May 2026, Dr. Haridopolos has performed the interim duties of the Surgeon General in the absence of a Senate-confirmed nominee.

Julieta Bonvin Sallago, MD, of Connecticut has been awarded a Community Champion Award. An international medical graduate who personally lives with a rare disease, Dr. Bonvin Sallago is currently pursuing a career as a genetic counselor in the United States. She works actively in clinical trial recruitment at Connecticut Children’s Hospital within the Glycogen Storage Disease Program—the exact family of disorders for which she received her own diagnosis. Leveraging her scientific and cultural background, she has become a prominent leader within NORD’s volunteer community, supporting the planning and execution of Latino patient and family listening sessions and translating NORD Rare Disease Reports into Spanish. She also serves on the advisory committee for the NORD® Living Rare Study, where her efforts have been instrumental in engaging and recruiting Spanish-speaking participants.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Lily Emmanuel of Colorado is also a recipient of a Community Champion Award. As a passionate advocate and volunteer leader, Emmanuel works to expand rare disease awareness and build robust community connections throughout the western United States. Through her leadership with NORD Running for Rare® in Colorado, she has created inclusive platforms for individuals impacted by rare disorders to escape isolation, uniting them in advocacy and fundraising initiatives centered around wellness and fitness. By forging strategic relationships with hospitals, nonprofit organizations, local running groups, and patient communities, she has successfully expanded rare disease education and peer support, inspiring many others to follow her path.

Maureen Helgren, PhD, of Connecticut has received a Community Champion Award for transforming rare disease education by embedding it directly into the core medical curriculum at the Frank H. Netter, MD School of Medicine at Quinnipiac University. Dr. Helgren developed a dedicated rare disease course, established the annual Netter Rare Disease Symposium, and consistently integrates patients and advocates into classroom lectures to ensure future physicians master both the clinical realities and the lived experiences of rare conditions. Serving as faculty advisor for the university’s NORD Students for Rare® chapter, she empowers students from high school through medical school to engage in advocacy and attend NORD’s annual Rare Diseases and Orphan Products Breakthrough Summit® in Washington, D.C. Through mentorship and patient-centered pedagogy, Dr. Helgren is actively working to reduce diagnostic delays and cultivate a generation of physicians who advocate fiercely for the rare disease community.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Susan A. Berry, MD, of Minnesota has been recognized with a Medical & Scientific Trailblazer Award. Her distinguished career at the University of Minnesota Medical School NORD Rare Disease Center of Excellence exemplifies excellence in scaling rare disease research, accurate diagnosis, and clinical treatment. Her groundbreaking work addressing inborn errors of metabolism, conducted in close collaboration with advocacy organizations such as the National PKU Alliance, has defined a vital standard of care. Dr. Berry’s impact extends far beyond her clinical practice in Minnesota; she has served as an advisor on national newborn screening policies and a vocal advocate for medical foods and formulas. She also lends her expertise directly to NORD as a member of its Board of Directors and its Scientific & Medical Advisory Committee.

Stephen Kingsmore, MD, DSc, of California is also a recipient of a Medical & Scientific Trailblazer Award. Serving as the Founding President and CEO of the Rady Children’s Institute for Genomic Medicine, a NORD Rare Disease Center of Excellence at UC San Diego, Dr. Kingsmore has pioneered the clinical application of whole genome sequencing, established rapid genetic testing as an indispensable clinical tool, and developed the first comprehensive genomic carrier screening test. Recognizing that approximately 80% of rare diseases have a genetic origin, Dr. Kingsmore continues to work toward bringing advanced genetic screening and precision medicine to broader clinical settings through emerging digital platforms.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

Mark Skinner, JD, of New York has been honored with the Lifetime Achievement Award in recognition of his extensive history of advocacy leadership within the bleeding disorders community at local, national, and global levels. He has previously led both the World Federation of Hemophilia and the National Bleeding Disorders Foundation, a NORD Member organization, and has contributed his expertise to critical blood safety and supply matters as a member of the U.S. Health and Human Services Advisory Committee on Blood and Tissue Safety and Availability. As a champion of patient-centered outcomes research and principal investigator for the international Patient Reported Outcomes Burdens and Experiences (PROBE) study, Skinner ensures that the direct experiences of patients inform healthcare decision-making. Through his service on the NORD Board of Directors, the Institute for Clinical and Economic Review (ICER) board, and formerly the Patient-Centered Outcomes Research Institute (PCORI) Advisory Panel on Rare Disease, he has consistently elevated the patient voice across the entire rare disease spectrum.

Paridhi Tyagi of New Jersey is the recipient of the Youth Leadership Award. During her sophomore year at Millburn High School, Tyagi founded a genetics club and subsequently partnered with NORD Students for Rare to educate her peers and local community on genetic conditions and rare disorders. For Rare Disease Day 2024, she organized an informational display at her local public library and coordinated the sharing of patient narratives via her school’s morning announcements. Recognizing the importance of engaging younger demographics, she spent nearly a year establishing a collaborative framework with Girl Scouts USA focused on genetics and rare disease education, culminating in three workshops where participants explored genetics, DNA extraction, and the importance of inclusivity. Her efforts culminated in her attendance at the NORD Breakthrough Summit, where she participated alongside seasoned professionals.

NORD Announces the 2026 Rare Impact Award Honorees Advancing Innovation, Research, and Advocacy for Rare

"Each of these 2026 Rare Impact Award winners demonstrates the power we each have as individuals to drive change in our communities, whether that’s as an advocate, policymaker, scientist, or physician," Gavin said. "They inspire us all to persevere in our shared mission to alleviate the physical, emotional, and financial strain that rare diseases place on too many individuals and families."

The Community Champion, Policy Changemaker, Youth Leader, Lifetime Achievement, and Abbey S. Meyers Leadership Awardees will be formally recognized in person at the NORD Breakthrough Summit® taking place October 26–27 in Washington, D.C. The Scientific and Medical Trailblazer Awardees were previously honored earlier this year at the NORD® Rare Disease Scientific Symposium, while NORD CEO Pamela Gavin is presenting the Industry Innovation Awards directly to each recipient company and their staff at their respective U.S. corporate headquarters.

Evan Lee Salim

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya